Immunovant (IMVT) Competitors $15.29 -0.24 (-1.55%) Closing price 09/16/2025 04:00 PM EasternExtended Trading$15.28 -0.01 (-0.10%) As of 05:45 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock IMVT vs. SLNO, QGEN, BBIO, MRNA, VRNA, ELAN, ROIV, RVMD, GRFS, and RYTMShould you be buying Immunovant stock or one of its competitors? The main competitors of Immunovant include Soleno Therapeutics (SLNO), QIAGEN (QGEN), BridgeBio Pharma (BBIO), Moderna (MRNA), Verona Pharma PLC American Depositary Share (VRNA), Elanco Animal Health (ELAN), Roivant Sciences (ROIV), Revolution Medicines (RVMD), Grifols (GRFS), and Rhythm Pharmaceuticals (RYTM). These companies are all part of the "medical" sector. Immunovant vs. Its Competitors Soleno Therapeutics QIAGEN BridgeBio Pharma Moderna Verona Pharma PLC American Depositary Share Elanco Animal Health Roivant Sciences Revolution Medicines Grifols Rhythm Pharmaceuticals Immunovant (NASDAQ:IMVT) and Soleno Therapeutics (NASDAQ:SLNO) are both mid-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, profitability, analyst recommendations, institutional ownership, media sentiment, dividends, valuation and earnings. Which has more volatility and risk, IMVT or SLNO? Immunovant has a beta of 0.45, meaning that its share price is 55% less volatile than the S&P 500. Comparatively, Soleno Therapeutics has a beta of -2.72, meaning that its share price is 372% less volatile than the S&P 500. Do analysts prefer IMVT or SLNO? Immunovant presently has a consensus target price of $33.60, indicating a potential upside of 119.75%. Soleno Therapeutics has a consensus target price of $115.09, indicating a potential upside of 131.52%. Given Soleno Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Soleno Therapeutics is more favorable than Immunovant.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Immunovant 0 Sell rating(s) 3 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 2.83Soleno Therapeutics 0 Sell rating(s) 0 Hold rating(s) 11 Buy rating(s) 1 Strong Buy rating(s) 3.08 Is IMVT or SLNO more profitable? Soleno Therapeutics' return on equity of -73.74% beat Immunovant's return on equity.Company Net Margins Return on Equity Return on Assets ImmunovantN/A -80.99% -72.23% Soleno Therapeutics N/A -73.74%-56.67% Do institutionals and insiders believe in IMVT or SLNO? 47.1% of Immunovant shares are owned by institutional investors. Comparatively, 97.4% of Soleno Therapeutics shares are owned by institutional investors. 1.8% of Immunovant shares are owned by insiders. Comparatively, 6.4% of Soleno Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Which has higher earnings and valuation, IMVT or SLNO? Soleno Therapeutics is trading at a lower price-to-earnings ratio than Immunovant, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioImmunovantN/AN/A-$413.84M-$2.85-5.36Soleno TherapeuticsN/AN/A-$175.85M-$4.14-12.01 Does the media refer more to IMVT or SLNO? In the previous week, Soleno Therapeutics had 31 more articles in the media than Immunovant. MarketBeat recorded 34 mentions for Soleno Therapeutics and 3 mentions for Immunovant. Immunovant's average media sentiment score of 1.11 beat Soleno Therapeutics' score of 0.57 indicating that Immunovant is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunovant 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Soleno Therapeutics 6 Very Positive mention(s) 1 Positive mention(s) 12 Neutral mention(s) 2 Negative mention(s) 2 Very Negative mention(s) Positive SummarySoleno Therapeutics beats Immunovant on 9 of the 13 factors compared between the two stocks. Get Immunovant News Delivered to You Automatically Sign up to receive the latest news and ratings for IMVT and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IMVT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IMVT vs. The Competition Export to ExcelMetricImmunovantMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.71B$3.12B$5.73B$10.31BDividend YieldN/A2.36%5.90%4.63%P/E Ratio-5.3621.1676.3826.51Price / SalesN/A446.35521.37123.58Price / CashN/A45.4037.1760.46Price / Book3.689.6213.666.29Net Income-$413.84M-$53.28M$3.28B$270.51M7 Day Performance-5.62%1.01%0.88%1.95%1 Month Performance0.46%4.58%4.67%6.33%1 Year Performance-47.42%8.35%80.92%25.62% Immunovant Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IMVTImmunovant2.2955 of 5 stars$15.29-1.5%$33.60+119.8%-48.0%$2.71BN/A-5.36120Positive NewsSLNOSoleno Therapeutics4.4324 of 5 stars$72.30+3.6%$115.09+59.2%-5.8%$3.71BN/A-17.4630Short Interest ↑QGENQIAGEN4.4198 of 5 stars$47.62+0.1%$49.69+4.4%+0.7%$10.57B$1.98B28.135,765Positive NewsBBIOBridgeBio Pharma4.4191 of 5 stars$54.29+1.7%$63.35+16.7%+96.6%$10.20B$221.90M-13.27400Analyst ForecastMRNAModerna4.5264 of 5 stars$24.83-1.2%$42.88+72.7%-64.1%$9.78B$3.24B-3.305,800VRNAVerona Pharma PLC American Depositary Share2.2987 of 5 stars$106.300.0%$109.00+2.5%+252.4%$9.20B$42.28M-107.3730Positive NewsELANElanco Animal Health2.8224 of 5 stars$19.02+3.2%$17.33-8.9%+28.4%$9.16B$4.44B22.129,000Positive NewsROIVRoivant Sciences2.8033 of 5 stars$12.91-0.1%$16.38+26.8%+17.8%$8.82B$29.05M0.00860Positive NewsRVMDRevolution Medicines4.2693 of 5 stars$41.06+1.4%$72.00+75.4%+0.4%$7.57B$11.58M-9.12250Insider TradeAnalyst RevisionGRFSGrifols3.8935 of 5 stars$10.11-0.2%$10.30+1.9%+6.4%$6.96B$7.81B8.6423,822News CoverageGap UpRYTMRhythm Pharmaceuticals3.3137 of 5 stars$99.77-2.3%$101.57+1.8%+92.9%$6.78B$130.13M-33.15140Positive News Related Companies and Tools Related Companies SLNO Competitors QGEN Competitors BBIO Competitors MRNA Competitors VRNA Competitors ELAN Competitors ROIV Competitors RVMD Competitors GRFS Competitors RYTM Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IMVT) was last updated on 9/17/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immunovant, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Immunovant With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
